Active Not Recruiting PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT07020377

Dapagliflozin in Nonalcoholic Fatty Liver Disease (NAFLD) and Type 2 Diabetes Mellitus Patients (T2DM).

The Hepato-protective Effect of Dapagliflozin in Type 2 Diabetes Mellitus Patients (T2DM) With Nonalcoholic Fatty Liver Disease (NAFLD)

Sponsor: Alexandria University

Conditions Diabetes Mellitus Non Alcholic Fatty Liver Disease

Interventions Dapagliflozin (DAPA) Negative control Placebo

Updated 2 times since 2025 Last updated: Jun 11, 2025 Started: Jan 15, 2024 Primary completion: Dec 20, 2025 Completion: Dec 30, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07020377, this PHASE1/PHASE2 trial focuses on Diabetes Mellitus and Non Alcholic Fatty Liver Disease and remains ongoing. Sponsored by Alexandria University, it has been updated 2 times since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

2 versions recorded

Sep 2025 — Present [monthly]

Active Not Recruiting PHASE1/PHASE2
Jul 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE1/PHASE2

First recorded

Jan 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alexandria University
Amira Bisher,PhD
Egyptian Liver Hospital

Data source: Damanhour University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Al Mansurah, Egypt
• Alexandria, Egypt